Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;44(4):664-671.
doi: 10.1002/nur.22140. Epub 2021 May 16.

Injectable opioid agonist treatment: An evolutionary concept analysis

Marlene Haines  1 , Patrick O'Byrne  1
Affiliations

Injectable opioid agonist treatment: An evolutionary concept analysis

Marlene Haines et al. Res Nurs Health. 2021 Aug.

Abstract

Canada is currently in the midst of an overdose crisis. With new and innovative approaches desperately needed, injectable opioid agonist treatment (iOAT) should be considered as an integral treatment option to prevent even more fatalities. These programs provide injectable diacetylmorphine or hydromorphone to clients with severe opioid use disorders. Currently, they remain an under-executed and under-studied treatment modality. To better understand why this may be, we performed an evolutionary concept analysis as described by Rodgers. The attributes, antecedents, consequences, and surrogate terms of iOAT were unpacked and explored. Further, four themes were identified within the literature: (1) physical and mental health, (2) illicit drug use, (3) criminal behavior, and (4) ethical considerations. Recommendations surrounding the need for additional studies that focus on the perspectives of people who use opioids (PWUO), the necessity of nursing advocacy in iOAT, and the consideration of a changing illicit drug supply were explored. Further, theoretical analysis coupled with direct input from PWUO was discussed as a necessity to move forward with iOAT.

Keywords: harm reduction; heroin-assisted therapy; injectable opioid agonist treatment; opioid use disorder; overdose crisis; safer supply; substance use.

PubMed Disclaimer

References

REFERENCES

    1. Afolabi, M. , & Sodeke, S. (2017). Reconciling competence and consent in opioid-dependence research: The value of vulnerability rhetoric. The American Journal of Bioethics, 17(12), 48-50. https://doi.org/10.1080/15265161.2017.1388871
    1. Bansback, N. , Guh, D. , Oviedo-Joekes, E. , Brissette, S. , Harrison, S. , Janmohamed, A. , Krausz, M. , MacDonald, S. , Marsh, D. C. , Schechter, M. T. , & Anis, A. H. (2018). Cost-effectiveness of hydromorphone for severe opioid use disorder: Findings from the SALOME randomized clinical trial. Addiction, 113(7), 1264-1273. https://doi.org/10.1111/add.14171
    1. Berrigan, P. (2018). A review of literature assessing public opinion of heroin assisted treatment. Heroin Addiction & Related Clinical Problems, 20(4), 13-18.
    1. Blanken, P. , Hendriks, V. , Huijsman, I. , van Ree, J. , & van Den Brink, W. (2016). Efficacy of cocaine contingency management in heroin-assisted treatment: Results of a randomized controlled trial. Drug and Alcohol Dependence, 164, 55-63. https://doi.org/10.1016/j.drugalcdep.2016.04.018
    1. Blanken, P. , Hendriks, V. , Koeter, M. , van Ree, J. , & van Den Brink, W. (2012). Craving and illicit heroin use among patients in heroin-assisted treatment. Drug and Alcohol Dependence, 120(1-3), 74-80. https://doi.org/10.1016/j.drugalcdep.2011.06.025

MeSH terms

LinkOut - more resources